See the latest news and media coverage for Immunity Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biopharmaceutical company developing treatments for neurodegenerative and inflammatory diseases
immunitypharma.comLast updated
In short: Immunity Pharma reported positive Phase 2a results showing IPL344 slowed ALS progression and reduced neurofilament light.
Phase 2a trial results published in Muscle and Nerve show 58-64% slower ALSFRS-R progression, 27% NfL reduction, and improved survival versus controls. IPL344 was safe and well-tolerated.
Treatment was well tolerated with 48% slower ALSFRS-R decline. Benefits suggested in weight gain, respiration, survival. NfL reduction observed.
Phase 2a study shows mean 20% plasma NfL reduction in six participants. Data presented at ALS/MND symposium. Strengthens IPL344 therapy potential.
Disease progression slowed 50% in functional and respiratory endpoints. Favorable safety profile shown. Biomarker confirms Akt pathway activation.
JERUSALEM, April 7, 2025 /PRNewswire/ -- The results of a phase-2a clinical trial of IPL344 were published in Muscle and Nerve, the leading American scientific...
Track Immunity Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.
